By Dominic Chopping
--KKR is nearing a deal to buy E45 maker Karo Healthcare in a buyout that values the healthcare company at about 2.6 billion euros ($2.85 billion), Financial Times reports, citing unnamed sources.
--The U.S. private equity group bested a rival bid from PAI Partners to clinch the company behind over-the-counter medicines such as athlete's foot treatment Lamisil and moisturizer E45, paying 2.65 billion euros including debt, the people said, according to FT.
--Karo's current owner, EQT, struck a deal to take the business private in 2022, valuing it at about 1.4 billion euros. EQT first became a majority owner of Karo in 2019 when it was still a publicly-listed business.
-Karo, EQT and PAI declined to comment while KKR did not immediately respond to a request for comment, FT says.
Full story: https://tinyurl.com/4va2f8wt
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
April 09, 2025 01:47 ET (05:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。